Oral glucose tolerance testing to find hidden type 2 diabetes in at-risk people in Guadeloupe

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Because fasting blood glucose (FBG) alone may miss diabetes in people of Afro‑Caribbean and Indo‑Caribbean descent, this project uses OGTT to screen adults with normal FBG but risk factors and HbA1c 5.7–6.4%. Eligible participants (ages 18–65) will have an OGTT at the hospital and a 2‑hour glucose ≥11 mmol/L (200 mg/dL) will confirm diabetes. Diagnosed participants will be treated according to national recommendations and monitored over one year, while those with normal OGTT will repeat testing at 12 months. The study aims to estimate how many additional diabetes cases OGTT detects compared with FBG in this specific population.

Why it matters

Who can join: the full rules

o Inclusion criteria : Adult subject (over 18 years and under 65 years old) Subjects of African or Indian origin and self-declared Normal FBG levels (110mg/dL) HbA1c levels between 5.7 and 6.4% One or more of the following factors: BMI \> 25 kg/m2, family history of T2DM in the 1st and 2nd familial degree, hypertension, dyslipidemia.

Affiliation to the national social health system or equivalent Informed and written consent signed by the patient and the investigator (at the latest on the day of inclusion and before the completion of any research related exam)

o Exclusion criteria : Pregnant or lactating woman Women with a history of gestational diabetes Polycystic ovary syndrome Endocrine, hepatic or renal diseases affecting glycemic control Treatment that affect the metabolism of glucose or insulin Refusal to participate Subjects without adequate or impaired decisional abilities for consent to research and placed under guardianship, curatorship or safeguard of justice, person participating in another research including an exclusion period still in progress, severely impaired physical and / or psychological health, which, according to the investigator, may affect the compliance of the study participant

Where it's running

• Centre Hospitalier Universitaire de la Guadeloupe
  Pointe-à-Pitre, Guadeloupe, Guadeloupe Recruiting

Study contacts

• Principal investigator: Fritz-Line VELAYOUDOM, Doctor — CHU de la Guadeloupe
• Study coordinator: Valérie HAMONY-SOTER
• Email: valerie.soter@chu-guadeloupe.fr
• Phone: +590 590 93 46 77

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Glucagon's effects on blood sugar in people with and without bariatric surgery

  This study tests whether giving glucagon or blocking its receptor changes short-term blood sugar control in non-diabetic adults who either had bariatric surgery or did not.

  Recruiting at 2 sites Phase 1 The University of Texas Health Science Center at San Antonio · San Antonio, Texas and 1 other locations · NCT07212868

• How the triglyceride–glucose (TyG) index relates to heart artery imaging in non‑diabetic adults with early coronary artery disease

  This study will see if the triglyceride–glucose (TyG) index helps explain angiographic patterns in non‑diabetic adults who develop coronary artery disease at younger ages.

  Recruiting Sohag University · Sohag · NCT07154186

• ANXV (Annexin A5) infusions for non-proliferative diabetic retinopathy and retinal vein occlusion

  This will test whether short daily infusions of ANXV can be given safely and help improve vision or reduce the need for rescue medication in adults with recent-onset non-proliferative diabetic retinopathy or retinal vein occlusion.

  Recruiting Phase 2 Annexin Pharmaceuticals AB · London · NCT07259928

• OTX-TKI (axitinib intravitreal implant) for non-proliferative diabetic retinopathy

  This trial will test whether a long-acting axitinib hydrogel implant injected into one eye can slow worsening in adults with moderately severe to severe non-proliferative diabetic retinopathy.

  Recruiting Phase 3 Ocular Therapeutix, Inc. · Hagerstown, Maryland · NCT07235085

• Evaluating TNTL for treating non-proliferative diabetic retinopathy

  This study is testing if a new drug called TNTL can help adults with non-proliferative diabetic retinopathy see better and stay safe compared to a placebo.

  Recruiting at 30 sites Phase 3 Beletalent (Zhuhai) Pharmaceutical Co., Ltd · Xuancheng, Anhui and 29 other locations · NCT06817265

• Remote ischemic conditioning to treat early diabetic retinopathy

  This trial will test whether remote ischemic conditioning — brief, repeated arm cuff inflations — helps adults aged 40–80 with mild-to-moderate non-proliferative diabetic retinopathy.

  Recruiting Xuanwu Hospital, Beijing · Beijing, Beijing Municipality and 1 other locations · NCT06713720

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.